MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Plant-Based Biopesticide Achieves 100% Control of Root-Rot Disease in Recent Studies

February 16, 2021 11:39:12
  • Most recent tests show MustGrow’s patented biopesticide achieved 100% control over Aphanomyces within 24 hours
  • Plant-based biopesticide uses natural defense mechanism found in mustard seed to control diseases, pests and weeds
  • MustGrow hoping to provide valuable crop-protection tool for pulse-crop farmers

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide has achieved 100% control of root-rot disease in a recent round of laboratory tests ( MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, is focused on providing natural, science-based biological solutions to replace synthetic chemicals in the cultivation process.

MustGrow’s safe and effective organic biopesticide is plant based; it uses a natural defense mechanism found in the mustard seed to control diseases, pests and weeds. In a recent round of tests, which were conducted by an independent third-party lab, MustGrow’s patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates.

“It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates,” said MustGrow COO Colin Bletsky. “The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply. I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.”

Aphanomyces is a soil-borne, root-rot disease that destroys peas, lentils and legume crops, commonly referred to as pulse crops. In infected fields, the disease can result in yield losses ranging from 10% to 100% complete destruction. The ability to control the disease using an organic, plant-based biopesticide could have a significant impact on the harvests of farmers seeking to eradicate the disease.

For instance, in 2019 Canada produced 9.2 million tons of pulse crops, making it one of the world’s largest producers. One study reported that Aphanomyces caused $20 million in annual pulse crop losses in Canada and $100 million worldwide. Currently the only available treatments slow down the spread in an attempt to reduce the severity of the disease; no treatments exist that control the devastating root-rot plague. MustGrow’s plant-based biopesticide aims to change that.

With the most recent lab results in, MustGrow is now looking forward to evaluating its proprietary product in larger-scale greenhouse and field tests. MustGrow’s biopesticide is applied to the soil before crops are planted. The greenhouse and field tests are a significant step forward in the progression and preparation of the product for commercial use and application.

This agriculture biotech company, which is focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, appears poised to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.